Analyst Opinions: Changes for Publicis, Sanofi, Amundi...
This Wednesday, February 4, 2026, several financial analysts are adjusting their price targets on listed stocks. These revisions particularly affect stocks in the communications, health, and asset management sectors.
Ayvens: JP Morgan raises its price target from €10.30 to €13.10. Recommendation remains neutral.
Publicis Groupe SA: Deutsche Bank lowers its target from €95 to €90, recommendation to hold. Citi reduces its target from €109 to €99, recommendation to buy. Huber Research Partners LLC decreases its target from €100 to €90, recommendation to overweight. Barclays lowers its target from €115 to €95 and revises its recommendation from overweight to market weight. BNP Paribas Exane reduces its target from €130 to €125, recommendation to outperform.
Sartorius Sted Bio: Oddo BHF lowers its target from €254 to €248, recommendation to outperform. Goldman Sachs reduces its target from €246 to €235, recommendation to buy. Jefferies adjusts its target from €236 to €256, recommendation to buy. Barclays lowers its target from €250 to €230, recommendation to overweight. Kepler Cheuvreux lowers its target from €95 to €85, recommendation to hold.
Valneva: Oddo BHF raises its price target from €7 to €8. Recommendation to outperform.
Teleperformance: Goldman Sachs lowers its target from €82 to €70. Recommendation remains neutral.
Sopra Steria Group: Oddo BHF raises its target from €250 to €257. Recommendation to outperform.
Sanofi: HSBC reduces its target from €98 to €95. Recommendation remains to buy.
Mersen: BNP Paribas Exane raises its target from €22 to €25. Recommendation remains neutral.
Atos: Oddo BHF increases its target from €55 to €59. Recommendation remains neutral.
Amundi: Oddo BHF raises its target from €80 to €84, recommendation to outperform. Mediobanca sets a target of €75 with a neutral recommendation. Goldman Sachs raises its target from €79 to €89, recommendation to buy. BNP Paribas Exane raises its target from €71 to €80, recommendation to hold.